Levitee Labs Inc.
Levitee Labs Inc.
Your view on LVTTF
Overview
What the company does, where it operates, and who runs it.
About Levitee Labs Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- David Bentil
- Headquarters
- 800 West Pender Street, Vancouver, BC, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- David Bentil
- Headquarters
- 800 West Pender Street, Vancouver, BC, CA
Levitee Labs Inc., a multidisciplinary integrative wellness company, provides evidence-based alternative medicines and novel psychedelic therapies. The company operates through two segments, Medical Services and Selling Products.
It offers treatments and medications for substance use disorders and chronic pain, such as myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome, as well as hepatitis-C and mental health conditions.
The company operates five clinics under the Levitee Clinics name; and three pharmacies in Alberta under the Levitee Pharmacies name. In addition, it offers electronic-prescriptions in the addiction treatment space under the BlockMD name; and wholesales supplements and superfood under the Earth Circle Organics name.
The company was formerly known as Fibonacci Capital Corp. and changed its name to Levitee Labs Inc. in November 30, 2020. Levitee Labs Inc. was incorporated in 2019 and is based in Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Levitee Labs Inc., and the rating behind it. LVTTF last traded at $0.0027; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Levitee Labs Inc.. Starting points for Levitee Labs Inc.: EPS -$0.27, beta 0.28 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Levitee Labs Inc.. Levitee Labs Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Levitee Labs Inc.. Trailing twelve-month EPS for Levitee Labs Inc. stands at -$0.27. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Levitee Labs Inc.. Levitee Labs Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Levitee Labs Inc. valued side by side against its closest peers. Levitee Labs Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Levitee Labs Inc., and how their positions are changing. At a $369,155 market value, institutional positions materially move Levitee Labs Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Levitee Labs Inc. executives and directors. Shares of Levitee Labs Inc. have traded between $0.0000 and $0.0027 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Levitee Labs Inc.. Levitee Labs Inc. is a $369,155 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Levitee Labs Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Levitee Labs Inc.. Coverage tracks Levitee Labs Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.